1422955-31-4 Usage
Uses
Used in Pharmaceutical Industry:
2,1,3-Benzoxadiazol-5-aMine, N-(3-chloro-5-fluorophenyl)-4-nitrois used as a chemical intermediate for the synthesis of various pharmaceutical compounds. Its unique structure and functional groups make it a valuable building block for the development of new drugs with specific therapeutic properties.
Used in Chemical Research:
2,1,3-Benzoxadiazol-5-aMine, N-(3-chloro-5-fluorophenyl)-4-nitrois also utilized in chemical research as a model system to study the reactivity and properties of benzoxadiazole derivatives. Researchers can use 2,1,3-Benzoxadiazol-5-aMine, N-(3-chloro-5-fluorophenyl)-4-nitro- to gain insights into the behavior of similar molecules and develop new synthetic strategies or applications.
Used in Material Science:
2,1,3-Benzoxadiazol-5-aMine, N-(3-chloro-5-fluorophenyl)-4-nitromay also find applications in the field of material science, particularly in the development of new materials with specific properties. Its unique structure and functional groups could contribute to the creation of materials with enhanced performance characteristics, such as improved stability, reactivity, or selectivity.
References
1) Scheuermann?et al.?(2013),?Allosteric inhibition of hypoxia inducible factor-2 with small molecules; Nat. Chem. Biol.,?9?271
2) Masetti?et al.?(2014),?Protein dynamics of the HIF-2α PAS-B domain upon heterodimerization and ligand binding; PLoS One,?9(4)?e94986
3) Rodgers?et al.?(2013),?Development of inhibitors of the PAS-B domain of the HIF-2α transcription factor; J. Med. Chem.,?56 1739
Check Digit Verification of cas no
The CAS Registry Mumber 1422955-31-4 includes 10 digits separated into 3 groups by hyphens. The first part of the number,starting from the left, has 7 digits, 1,4,2,2,9,5 and 5 respectively; the second part has 2 digits, 3 and 1 respectively.
Calculate Digit Verification of CAS Registry Number 1422955-31:
(9*1)+(8*4)+(7*2)+(6*2)+(5*9)+(4*5)+(3*5)+(2*3)+(1*1)=154
154 % 10 = 4
So 1422955-31-4 is a valid CAS Registry Number.
1422955-31-4Relevant academic research and scientific papers
INHIBITION OF HIF-2α HETERODIMERIZATION WITH HIF1β (ARNT)
-
Paragraph 093, (2014/06/11)
Provided is a method of inhibiting heterodimerization of HIF-2α to HIF1β (ARNT) comprising binding certain small molecules to the HIF-2α PAS-B domain cavity but not to HIF1α and inhibiting HIF-2α heterodimerization to HIF1β (ARNT) but not inhibiting HIF1α
Development of inhibitors of the PAS-B domain of the HIF-2α transcription factor
Rogers, Jamie L.,Bayeh, Liela,Scheuermann, Thomas H.,Longgood, Jamie,Key, Jason,Naidoo, Jacinth,Melito, Lisa,Shokri, Cameron,Frantz, Doug E.,Bruick, Richard K.,Gardner, Kevin H.,MacMillan, John B.,Tambar, Uttam K.
supporting information, p. 1739 - 1747 (2013/03/29)
Hypoxia inducible factors (HIFs) are heterodimeric transcription factors induced in a variety of pathophysiological settings, including cancer. We describe the first detailed structure-activity relationship study of small molecules designed to inhibit HIF-2α-ARNT heterodimerization by binding an internal cavity of the HIF-2α PAS-B domain. Through a series of biophysical characterizations of inhibitor-protein interactions (NMR and X-ray crystallography), we have established the structural requirements for artificial inhibitors of the HIF-2α-ARNT PAS-B interaction. These results may serve as a foundation for discovering therapeutic agents that function by a novel mode of action.
